Den Europæiske Union - dansk - EMA (European Medicines Agency)

pfizer europe ma eeig - gemtuzumab ozogamicin - leukæmi, myeloid, akut - antineoplastiske midler - mylotarg er angivet for kombinationsbehandling med daunorubicin (dnr) og cytarabine (arac) til behandling af patienter, alder 15 år og derover med tidligere ubehandlet, de novo cd33-positive akut myeloid leukæmi (aml), bortset fra akut promyelocyt leukæmi (apl).

Den Europæiske Union - dansk - EMA (European Medicines Agency)

pfizer europe ma eeig - talazoparib - bryst neoplasmer - antineoplastiske midler - talzenna er angivet som monoterapi til behandling af voksne patienter med germline brca1/2 mutationer, der har her2-negative lokalt fremskreden eller metastatisk brystkræft. patients should have been previously treated with an anthracycline and/or a taxane in the (neo)adjuvant, locally advanced or metastatic setting unless patients were not suitable for these treatments. patienter med hormon receptor (hr)-positiv brystkræft skulle have været behandlet med en forudgående endokrine-baseret terapi, eller anses uegnet til at endokrine-baseret terapi.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

pfizer europe ma eeig - lorlatinib - carcinom, ikke-småcellet lunge - antineoplastic agents, protein kinase inhibitors - lorviqua as monotherapy is indicated for the treatment of adult patients with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc) previously not treated with an alk inhibitor. lorviqua as monotherapy is indicated for the treatment of adult patients with alk‑positive advanced nsclc whose disease has progressed after:alectinib or ceritinib as the first alk tyrosine kinase inhibitor (tki) therapy; orcrizotinib and at least one other alk tki.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

pfizer europe ma eeig - dacomitinib monohydrat - carcinom, ikke-småcellet lunge - antineoplastiske midler - vizimpro, som monoterapi, er angivet for den første linje behandling af voksne patienter med lokalt fremskreden eller metastatisk ikke-småcellet lungekræft (nsclc) med epidermal growth factor receptor (egfr) aktiverende mutationer.

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

nordic prime aps - betamethasondipropionat - creme - 0,5 mg/g

Den Europæiske Union - dansk - EMA (European Medicines Agency)

pfizer europe ma eeig  - crisaborole - dermatitis, atopisk - andre dermatologiske præparater - staquis er indiceret til behandling af mild til moderat atopisk dermatitis hos voksne og pædiatriske patienter fra 2 år med ≤ 40% legemsoverflade (bsa), der berøres.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

pfizer europe ma eeig - glasdegib maleate - leukæmi, myeloid, akut - antineoplastiske midler - daurismo is indicated, in combination with low-dose cytarabine, for the treatment of newly diagnosed de novo or secondary acute myeloid leukaemia (aml) in adult patients who are not candidates for standard induction chemotherapy.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vacciner - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. brug af denne vaccine bør være i overensstemmelse med de officielle anbefalinger.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

pfizer europe ma eeig  - abrocitinib - dermatitis, atopisk - andre dermatologiske præparater - cibinqo is indicated for the treatment of moderate-to-severe atopic dermatitis in adults who are candidates for systemic therapy.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

pfizer europe ma eeig - somatrogon - growth and development - hypofysen og hypothalamus hormoner og analoger - indicated for the long-term treatment of paediatric patients with growth disturbance due to insufficient secretion of growth hormone.